Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed vel viverra mi, et tempor dolor. Vestibulum feugiat, ante id mattis imperdiet, purus massa imperdiet dui, ultricies vestibulum lorem nibh a velit.
Our Life Sciences Legal Forum offers quarterly sessions focusing on hot topics within the life sciences sector.
Our Life Sciences Legal Forum offers a series of quarterly sessions focusing on hot topics within the life sciences sector. In a recent webinar, we explored the complexities of borderline products, focusing on categories that often raise challenging questions.
Our Life Sciences Legal Forum offers a series of quarterly sessions focusing on hot topics within the life sciences sector. In a recent webinar, we took a step back to consider trends and challenges in life sciences fundraising and corporate transactions
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has released a draft guideline, ICH E21 (available here), focusing on the inclusion of pregnant and breastfeeding women in clinical trials.
At the recent Westminster Health Forum conference on rare diseases, Stephanie Caird reflected on the evolving clinical trials landscape in the UK and how this could affect the future of research into rare diseases and the unique challenges these bring with them.
In the life sciences sector, ownership of core intellectual property (IP) is crucial. It can significantly influence a business's valuation. So it is essential to ensure that contracts with employees and consultants clearly address IP ownership, especially when they are involved in creating or contributing to valuable innovations.
The Department for Science, Innovation and Technology (DSIT) has recently announced that multinational biotech business BioNTech will invest up to £1 billion over 10 years in its UK activities, supported by £129 million in grant funding from government over that period.
Research collaborations are set up to produce innovative results and potentially valuable intellectual property.
On 18 March 2025, I chaired a panel which discussed the current issues with clinical trials and representation of women participants in the current data sets.
Medicines expenditure in the UK is tightly controlled, with detailed national arrangements in place to manage costs.
Ongoing reform across the medical devices regimes in both the EU and the UK aim to ensure patient safety while providing a practical and proportionate system for manufacturers and innovators.